CD8A and cancer: Despite the controversial role of IL-33 in cancer immunity, it is extensively demonstrated that this epithelial-derived alarmin may provide anticancer responses in a number of tumors due to its ability to stimulate a wide set of immune cells, such as CD8+ T cells, NK, DCs, eosinophils and basophils that infiltrate the TME [38].